IVA.US Inventiva Sa

Healthcare Biotechnology USA Stocks
3.68 USD
Close of Nov 15, 2026
2.82 7.29
Market cap
USD 880M
P/E
-
P/B
13.44x
ROE
-838.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is IVA.US undervalued?

Graham number

The Graham number of Inventiva Sa cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Inventiva Sa fundamental analysis

No fundamental analysis for Inventiva Sa yet.

Inventiva Sa stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Inventiva Sa

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharido…

Full company profile